Novartis released two of three closely watched H2 2026 trial readouts on Sept. 5, with its cardiovascular drug pelacarsen missing its primary goal. Attention now shifts to the company's rare-disease treatment data as the next potential share-price driver.
A closely watched cardiovascular program at Novartis came up short this week, leaving the Swiss drug maker's rare-disease pipeline to carry the weight of investor expectations for the rest of 2026.
Pelacarsen, the heart drug Novartis developed with Ionis Pharmaceuticals, missed its key goal in a late-stage trial, one of two H2 2026 readouts the company released Sept. 5. The miss undercuts a cardiovascular asset Wall Street had counted among Novartis' second-half pipeline events, and attention now turns to the rare-disease treatment data as the next readout that could move the shares.
Novartis has not yet disclosed the specific efficacy or safety figures from the pelacarsen trial, nor the terms of its collaboration with Ionis. The rare-disease results are expected within the same H2 2026 data window, though the company has not set an exact release date. The two readouts were among three late-stage trials that analysts had flagged for the second half of the year, making the week a consequential test of Novartis' pipeline.
The heart drug setback pressures a program that was expected to help offset slowing growth in Novartis' core portfolio. A positive rare-disease readout would hand investors a fresh growth driver and could cushion the shares, while a miss would leave the pipeline thinner heading into 2027.
The net share impact depends on the market potential of the rare-disease asset relative to the cardiovascular program. Investors will watch for the rare-disease data release, the next named event on Novartis' H2 2026 calendar.
This article is for informational purposes only and does not constitute investment advice.
